Clinical Evidence
Sarr 2012

The EMPOWER Study: Randomized, Prospective, Double-Blind, Multicenter Trial of Vagal Blockage to Induce Weight Loss in Morbid Obesity

**DESCRIPTION**

| Prospective, randomized controlled, double-blind, multi-center trial (EMPOWER) | 294 implanted & randomized  
| n=192 treated subjects  •  n=102 control subjects  
| 15 centers |

**RESULTS & SUMMARY**

- vBloc was safe. Weight loss was not greater in treated group compared to control group; however, clinically important weight loss was related to hours of device use.
- Post-study analysis suggests low-charge delivered via the system checks may have contributed to weight loss in the control group.
- Device-related complications in 3% of subjects.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Treated</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>EWL (%)</td>
<td>17</td>
<td>16</td>
</tr>
<tr>
<td>EWL (%) ≥12 hours device use</td>
<td>30</td>
<td>22</td>
</tr>
</tbody>
</table>

To learn more, visit [www.vBloc.com](http://www.vBloc.com)